

2025 年英文論文業績

1. Jo T, Kondo T, Mizuno S, Kako S, Doki N, Uchida N, Tanaka M, Nishida T, Fukuda T, Sawa M, Kanda Y, Takada S, Hasegawa Y, Katayama Y, Yoshihara S, Kawamura K, Ohbiki M, Atsuta Y, **Yanada M**, Arai Y. Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia. **Blood Neoplasia**. 2025;2:100166.
2. Kobayashi S, Itonaga H, Kurosawa S, **Yanada M**, Miyazaki Y, Najima Y, Aoki J, Uchida N, Miyakoshi S, Doki N, Tanaka M, Uehara Y, Eto T, Anzai N, Onizuka M, Sawa M, Fukuda T, Asada N, Katayama Y, Kawakita T, Yoshimitsu M, Kanda J, Ohbiki M, Atsuta Y, Ishiyama K. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Myeloid Malignancies over 70 years old: A Retrospective Analysis of the Japanese Nationwide Registry. **Transplant Cell Ther**. 2025;31:822.e1-822.e11.
3. Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, **Yanada M**. Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy. **Br J Haematol**. 2025;207:484-497.
4. Teramoto M, Shimomura Y, Hosoi H, **Yanada M**, Mizuno S, Uchida N, Mori Y, Doki N, Takeda W, Katayama Y, Ota S, Nakamae H, Kuriyama T, Yoshihara S, Toyosaki M, Imada K, Sakata-Yanagimoto M, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Konuma T. Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia. **Bone Marrow Transplant**. 2025;60:1275-1277.
5. Saito T, Kusumoto S, **Yanada M**, Kato S, Kagami Y, Kawaguchi Y, Tajiri H, Hagiwara S, Hosoda W, Yamamoto K. RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma. **J Clin Exp Hematop**. 2025;65:158-161.
6. Kemmoku E, Kusumoto S, Kato S, Kawaguchi Y, Hagiwara S, Saito T, Tokumasu F, Nonaka A, **Yanada M**, Kinoshita T, Hosoda W, Yamamoto K.

Composite mantle cell lymphoma and T-cell prolymphocytic leukemia: a case report. **J Clin Exp Hematop.** 2025;65:107-114.

7. Shimizu T, Arai Y, Kondo T, Yano S, Shimomura Y, Doki N, Fukuda T, Nishida T, Takahashi S, Ota S, Kanda Y, Kuriyama T, Kurita N, Kawakita T, Hasegawa Y, Hiramoto N, Onizuka M, Atsuta Y, **Yanada M**. Improved post-transplant outcomes for elderly acute myeloid leukemia patients conditioned with FLU/BU4 rather than conventional MAC regimens. **Bone Marrow Transplant.** 2025;60:804-810.
8. **Yanada M**, Yamasaki S, Hosoi H, Mizuno S, Harada K, Doki N, Fujiwara SI, Hiramoto N, Hasegawa Y, Ishiwata K, Nishida T, Asada N, Suzuki T, Sakata-Yanagimoto M, Uchida N, Kanda J, Yoshimitsu M, Kanda Y, Fukuda T, Ohbiki M, Atsuta Y, Konuma T. Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia. **Bone Marrow Transplant.** 2025;60:894-896.
9. Arai Y, Brazauskas R, He N, Al-Homsi AS, Chhabra S, Battiwalla M, **Yanada M**, Steinberg A, Diaz Perez MA, Hong S, Kanda J, Bashey A, Frangoul HA, Badawy SM, Verdonck LF, Lazarus HM, Yared JA, Hashem H, Sharma A, Aljurf M, Dias AL, Abid MB, Wirk B, Freytes CO, Zeidan AM, Gergis U, Beitinjaneh A, Askar M, Pu JJ, Lehmann LE, Rangarajan HG, Wood WA, Hashmi S, Yano S, Kako S, Ozawa Y, Doki N, Kanda Y, Fukuda T, Katayama Y, Ichinohe T, Tanaka J, Teshima T, Okamoto S, Atsuta Y, Saber W. Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study. **EJHaem.** 2025;6:e70061.
10. Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N, Onizuka M, Miyakoshi S, Tanaka M, Takahashi S, Hayashi M, Kawakita T, Uehara Y, Ota S, Izumi T, Sawa M, Nishida T, Katayama Y, Nagafuji K, Kato K, Ichinohe T, Atsuta Y, **Yanada M**. Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55. **Bone Marrow Transplant.** 2025;60:458-466.
11. Yamasaki S, **Yanada M**, Araie H, Fukuda T, Kanda Y, Tashiro H, Uchida N, Ozeki K, Ota S, Onishi Y, Doki N, Oyake T, Takada S, Sakurai M, Kondo Y, Nakamae H, Kawakita T, Onizuka M, Atsuta Y, Konuma T. Comparative analysis of allogeneic hematopoietic cell transplantation in patients with therapy-related and de novo acute promyelocytic leukemia A retrospective study. **Sci Rep.** 2025;15:10967.

12. Shimomura Y, Kitamura T, **Yanada M**, Mizuno S, Kondo T, Yoshihara S, Tanaka M, Inai K, Katayama Y, Onizuka M, Fukuda T, Nakamae H, Kurokawa M, Yano S, Nara M, Masuko M, Miyakoshi S, Eto T, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Konuma T. Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission. **Cytotherapy**. 2025;27:316-323.
13. Mitsuyuki S, Shimomura Y, Mizumaki H, **Yanada M**, Mizuno S, Uchida N, Doki N, Ito A, Tanaka M, Nishida T, Katayama Y, Yoshihara S, Eto T, Takada S, Ota S, Toyosaki M, Hasegawa Y, Nakamae H, Kawamura K, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Konuma T. Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG. **Leukemia**. 2025;39:495-498.
14. Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M, Mori Y, Doki N, Nishida T, Kotani T, Ogata M, Tabayashi T, Eto T, Sawa M, Imada K, Kanda J, Ichinohe T, Atsuta Y, **Yanada M**. HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML. **EJHaem**. 2025;6:e21088.
15. Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, Ouchi F, Uchida N, Tanaka M, Nishida T, Fukuda T, Hasegawa Y, Sakata-Yanagimoto M, Onizuka M, Sawa M, Ota S, Asada N, Fujiwara SI, Yoshihara S, Ishimaru F, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, **Yanada M**. Different impacts of granulocyte colony- stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. **Am J Hematol**. 2025;100:66-77.
16. Hagiwara S, Ri M, Ebina T, Marumo Y, Nakamura T, Hirade K, Nakashima T, **Asano A**, Kinoshita S, Suzuki T, Narita T, Masaki A, Komatsu H, Iida S. Immunosuppressive Effects of Multiple Myeloma-Derived Extracellular Vesicles Through T Cell Exhaustion. **Cancer Sci**. 2025 Jul;116(7):1861-1870.
17. Suzuki T, Fujii K, Matsunaga N, Sasaki H, Kanamori T, **Asano A**, Kinoshita S, Narita T, Masaki A, Sanda T, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H. Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma. **Br J Haematol**. 2025;207:92-100.
18. Ri M, Iida S, Saito K, Saito Y, Maruyama D, **Asano A**, Fukuhara S,

Tsujimura H, Miyazaki K, Ota S, Fukuhara N, Negoro E, Kuroda J, Yoshida S, Ohtsuka E, Norifumi T, Tabayashi T, Takayama N, Saito T, Suzuki Y, Harada Y, Mizuno I, Yoshida I, Maruta M, Takamatsu Y, Katsuya H, Yoshimitsu M, Minami Y, Kanato K, Munakata W, Nagai H. Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). **Cancer Chemother Pharmacol.** 2025;95:29.